Respicardia Announces First U.S. Commercial Case with the remedē® System; Industry Veteran Peter Sommerness Joins as CEO to Lead U.S. Launch

MINNETONKA, Minn., Feb. 2, 2018 /PRNewswire/ — Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, announced today that the first U.S. commercial case using the remedē® System to treat central sleep apnea was completed at The Ohio State University Wexner Medical Center in Columbus, Ohio by Ralph Augostini, MD, FACC, FHRS, Bob and Corrine Frick Chair in Cardiac Electrophysiology, Associate Professor of Medicine and co-director of the electrophysiology training program. The first case coincides with the naming of season medical device executive, Peter Sommerness, as CEO of Respicardia and the leader of the remedē® system U.S. launch…